Harun M. Patelab,
Pankaj Barib,
Rajshekhar Karpoormatha,
Malleshappa Noolvic,
Neeta Thapliyala,
Sanjay Suranab and
Pritam Jain*b
aDept. of Pharmaceutical Chemistry, University of KwaZulu-Natal (Westville Campus), Private Bag X54001, Durban-4000, South Africa
bDepartment of Pharmaceutical Chemistry, R.C. Patel College of Pharmacy, Shirpur, Dhule 425405, Maharashtra, India. E-mail: pritash79@yahoo.com; Fax: +91-2563-251808; Tel: +91-2563-255189
cDepartment of Pharmaceutical Chemistry, Shree Dhanvantary Pharmacy College, Kim, Surat-3941110, Gujarat, India
First published on 4th June 2025
Retraction of ‘Design and synthesis of VEGFR-2 tyrosine kinase inhibitors as potential anticancer agents by virtual based screening’ by Harun M. Patel et al., RSC Adv., 2015, 5, 56724–56771, https://doi.org/10.1039/C5RA05277G.
In the Experimental section, with the exception of compound 41, the reported yields and melting points of all compounds are incorrect.
The 1H NMR data reported in the Experimental section and the associated spectra in the supplementary information for compounds 26, 29 and 55 are incorrect.
The HRMS data reported in the Experimental section and the associated spectra in the supplementary information for compounds 3, 22, 26, 29, 47, 55 and 69 are incorrect.
In addition, all IC50 values in the article have been incorrectly reported as nM rather than μM.
The number and type of errors identified means that the Editor has lost confidence in the overall reliability of the article and therefore this paper is being retracted.
The authors were informed about the retraction. Harun M. Patel responded but did not state whether they agreed with the decision. The other authors have not responded.
Signed: Laura Fisher, Executive Editor, RSC Advances
Date: 20th May 2025
This journal is © The Royal Society of Chemistry 2025 |